ΔNp63 promotes IGF1 signalling through IRS1 in squamous cell carcinoma

Valentina Frezza¹, Claudia Fierro¹, Elena Gatti², Angelo Peschiaroli³, Anna Maria Lena¹, Margherita Annicchiarico Petruzzelli⁴, Eleonora Candi¹,⁴, Lucia Anemona¹, Alessandro Mauriello¹, Pier Giuseppe Pelicci², Gerry Melino¹,⁵, Francesca Bernassola¹

¹Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, Rome 00133 Italy
²Department of Experimental Oncology, European Institute of Oncology, Milan 20139 Italy
³National Research Council of Italy, Institute of Translational Pharmacology (IFT-CNR), Rome 00133 Italy
⁴Istituto Dermopatico dell’Immacolata, IRCCS, Rome 00163 Italy
⁵Medical Research Council, Toxicology Unit, University of Cambridge, Leicester LE1 9HN, UK

Correspondence to: Francesca Bernassola, Gerry Melino; email: bernasso@uniroma2.it, melino@uniroma2.it
Keywords: p53 family, p63, IGF system, IRS1, head and neck tumours
Received: October 24, 2018 Accepted: December 12, 2018 Published: December 28, 2018
Copyright: Frezza et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Accumulating evidence has proved that deregulation of ΔNp63 expression plays an oncogenic role in head and neck squamous cell carcinomas (HNSCCs). Besides p63, the type 1-insulin-like growth factor (IGF) signalling pathway has been implicated in HNSCC development and progression. Most insulin/IGF1 signalling converges intracellularly onto the protein adaptor insulin receptor substrate-1 (IRS-1) that transmits signals from the receptor to downstream effectors, including the PI3K/AKT and the MAPK kinase pathways, which, ultimately, promote proliferation, invasion, and cell survival. Here we report that p63 directly controls IRS1 transcription and cellular abundance and fosters the PI3K/AKT and MAPK downstream signalling pathways. Inactivation of ΔNp63 expression indeed reduces tumour cell responsiveness to IGF1 stimulation, and inhibits the growth potential of HNSCC cells. In addition, a positive correlation was observed between p63 and IRS1 expression in human HNSCC tissue arrays and in publicly available gene expression data. Our findings indicate that aberrant expression of ΔNp63 in HNSSC may act as an oncogenic stimulus by altering the IGF signalling pathway.

INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC), the sixth most frequent malignancy worldwide, is a heterogeneous disease that develops from the stratified epithelium of the upper aerodigestive tract [1]. Despite recent diagnostic and therapeutic advances, the prognosis and survival of HNSCC patients remain poor. In response to the increase in the number of new HNSCC cases worldwide, further knowledge of tumour biology and the identification of novel clinical biomarkers are needed to improve prognostic stratification and optimise the anti-cancer therapies.

The p53 family of transcription factors includes p53, p63 and p73, which are all involved in tumorigenesis [2-8] as well as in fertility [9, 10], metabolism [11], and aging [12-17] regulation. In addition, a developmental or differentiation function has been described for all the family members [18-32]. Many of these features are compatible with the genetic [33-37] and metabolic [38-45] events described in aging [46-55]. A common feature of the p53 family members is the presence of two distinct promoters that can be differentially used to transcribe the full-length (TA isoforms) or the N-terminal-shorter (ΔN isoforms) proteins, exerting distinct functions [56]. ΔNp63 is the predominant isoform
may have a prognostic impact and a proliferative resistance [59, 66, 68, 69]. HNSCC patients [66, 70]. Although some overexpression is an adverse prognostic factor for which signalling in HNSCCs [65-67], in which ΔNp63 promotes cancer cell survival, proliferation and chemoresistance [59, 66, 68, 69]. ΔNp63 overexpression is an adverse prognostic factor for HNSCC patients [66, 70]. Although some ΔNp63 targets and molecular pathways relevant for its pro-tumorigenic activities have been identified [59, 66, 71, 72], there still need to uncover the molecular basis of its oncogenic function.

The Insulin-like Growth Factor (IGF) axis is composed of the tyrosine kinase IGF type 1 receptor (IGF1R), its ligands, insulin, IGF1 and IGF2, the adaptor protein Insulin Receptor Substrate 1 (IRS1) and a family of six ligand-binding proteins (IGFBPs) that regulate the bioavailability and half-life of circulating IGF1. Among the IGFBPs, IGFBP3 binds to more than 95% of circulating IGF. The IGF1R binds IGF1 and IGF2 with high affinity, as well as insulin, though with lower affinity. Upon ligation, IGF1R recruits and phosphorylates IRS1. Phosphorylated IRS1 acts as docking site for intracellular adaptor proteins that, ultimately, activate two downstream signalling cascades: the PI3K/AKT and the MAPK pathways, both of which have mitogenic and pro-survival roles.

Reduced responsiveness to IGF1/insulin can occur as a result of diminished total or phosphorylated amounts of IGF1R or IRS1, and results in decreased activation of the PI3K/AKT and MAPK pathways, both of which have mitogenic and pro-survival roles.

Deregulation of the IGF axis has been implicated in the development and progression of several human cancers. Elevated serum IGF1 levels, and increased levels or constitutive activation of IGF1R and IRS1 are associated with increased risk of a variety of epithelial cancers, metastasis and therapeutic resistance [74-80]. Hence, it has been proposed that reduction of IGF signalling may have a prognostic impact and a therapeutic benefit in some cancer types. In HNSCC, IGF1R overexpression is associated with adverse survival, HPV negativity and high tumour T-stage [76, 81, 82]. High IGF1 levels and both lower and higher levels of IGFBP3 are predictor risk factors for secondary tumour development in patients with HNSCC [83, 84]. In addition, increased IRS1 expression was found in nasopharyngeal carcinoma patients, where it correlated with lymph node metastasis [80]. Notably, the existence of a possible crosstalk between p63 and the IGF system has been reported. The tumour suppressive TAp63 isoforms negatively control Igf1r transcription [85], whereas Igfbp3 is a target of transcriptional repression by ΔNp63 [86]. Here we report, that ΔNp63 affects the transcription and the cellular abundance of Irs1 in HNSCC cells and, that, as a result, p63 down-regulation impairs the activation of the intracellular signalling pathways following IGF1R stimulation.

RESULTS

p63 controls IRS1 expression levels in HNSCC cells

By exploiting RNA sequencing (RNA-seq) transcriptome profiling, we identified genes regulated by ΔNp63 in normal human epidermal keratinocytes (NHEKs) (E.C. unpublished data). The analysis of RNA-Seq data obtained from p63-depleted cells revealed almost 50% reduction in IRS1 expression levels relatively to control cells (Fig. 1A). We then sought to test whether IRS1 expression is regulated by p63 in HNSCC cells. HNSCC cell lines display moderate/high levels of p63 expression (Fig. 1B, upper panel). In particular, the predominantly expressed isoform of p63 in HNSCC cells is ΔNp63, with TAp63 being undetectable in the majority of the cell lines (Fig. 1C). We observed a consistent correlation between ΔNp63 protein levels and the gene expression pattern of IRS1 in most of the HNSCC cell lines analysed (Fig. 1B, lower panel). Validation of RNA-seq data showed that, following p63 knockdown, IRS1 transcript and protein levels were reduced in NHEK and in a panel of HNSCC cell lines (Fig. 1D).

p63 induces IRS1 expression by binding directly to the regulatory region of the Irs1 gene

Genome-wide profiling of p63 binding sites by Chromatin IP Sequencing (ChIP-seq) analysis of NHEKs [87] revealed peaks of p63 binding to regions downstream the Irs1 locus (Fig. 2A). The algorithm p63scan identified a putative p63 responsive element (RE) in the most distant enriched peak. To validate direct interaction of p63 with this putative RE, we examined p63 occupancy at the site identified in the ChIP-seq analysis. By ChIP experiments in HNSCC cells, we found binding of p63 to a regulatory region located downstream the Irs1 locus (+148 kbps from the TSS) (Fig. 2B). In addition, by performing luciferase activity reporter assays in H1299 cells, we found that the ΔNp63 isoforms activate a luciferase reporter gene driven by the p63 RE located in the regulatory region of the Irs1 locus (Fig. 2C). Site-specific mutagenesis of the p63 RE almost completely abrogated the transactivating
ability of ΔNp63 (Fig. 2C). Overall, these data demonstrate that Irs1 is a direct transcriptional target of ΔNp63.

p63 inactivation impairs cellular sensitivity of HNSCC cells to IGF1/insulin stimulation

We next tested whether knockdown of ΔNp63 affects the level of activated IRS1. To assess whether down-regulation of IRS1 in p63-depleted HNSCC cells would impair cellular responsiveness to receptor stimulation, we treated serum starved Fadu cells with both IGF1 and insulin. Stimulation of the IGF1R resulted in reduced levels of phosphorylated (Ser612) IRS1 in p63-depleted relatively to control cells (Fig. 3A). To rule out off-target effects, two independent siRNAs against p63 and one specific ΔNp63 siRNA were employed (Fig. 3A, Fig. S1A, and S1B).

To examine whether alteration of IRS1 and phospho-IRS1 levels induced by p63 silencing may affect downstream IGF signal transduction, we measured the activation of PI3K/AKT and MAPK downstream signalling pathways in p63-depleted cells. Upon p63 knock-down, we observed desensitization of HNSCC cells to IGF1 stimulation, as assessed by decreased amounts of phospho-AKT (Ser473) and phospho-S6 (Ser235/236) (Fig. 3B). Activation of MAPK (phospho-Erk1/2; Thr202/Tyr204) signalling pathway in response

Figure 1. IRS1 expression is decreased upon down-regulation of p63 in HNSCC cell lines. (A) Relative expression levels of irs1 as measured by RNA-Seq analysis of p63-depleted NHEK. Cells were transfected with p63 (sip63#1) or scrambled control (siScr) siRNAs. P-value = 0.005. (B) The amount of p63 was measured in NHEK and HNSCC cell lines by western blot analysis (upper panel). IRS1 transcript levels were analysed by RT-qPCR (lower panel). RT-qPCR was performed in duplicate. IRS1 expression was normalized on Tbp housekeeper and plotted relative to NHEK cells (mean ± s.d.). (C) The transcript levels of TAp63 (black box) and ΔNp63 (grey box) were measured in NHEK and HNSCC cell lines by RT-qPCR. RT-qPCR was performed as above. Gene expression was normalized on Tbp housekeeper and plotted relative to NHEK cells (mean ± s.d.). (D) RT-qPCR analysis (upper panels) of two independent experiments performed in duplicates for irs1 transcripts in NHEK and HNSCC cells transfected with scrambled control (siScr) or p63 (sip63#1) siRNAs. Cells were harvested 48 h after transfection. qRT-PCR was performed as above. Values are normalized to Tbp and plotted relative to control cells (mean ± s.d.). Western blot analysis for IRS1 and p63 in HNSCC cells transfected as above. Cells were harvested 48 h after transfection. β-actin served as loading control.
to IGF-1 stimulation was also markedly reduced in p63-depleted cells (Fig. 3B), further proving that p63 affects cellular sensitivity to IGF1/insulin stimulation through the regulation of IRS1 cellular abundance. Notably, knockdown of IRS1 hampered the proliferation of HNSCC cells, mimicking the effect of p63 inactivation (Fig. 3C). These findings indicate that the p63/IRS1 functional axis positively regulates the growth potential of HNSCC cells.

**p63 and IRS1 expression correlates in HNSCC patients**

To examine possible correlations between the expression levels of Np63 and IRS1 in HNSCC primary tumours, clinical HNSCC tumour specimens and related benign controls were examined for p63 and IRS1 staining on tissue microarray slides. Consistent with previous reports [65, 66], the majority of the patients (63%) showed high levels of p63 expression (Fig. 4A; representative staining patterns are seen in Fig. 4C, top panels). High and moderate tumour cell IRS1 expression was observed in 27% and 10%, respectively of the cases (Fig. 4B, representative staining patterns are seen in Fig. 4C, bottom panels). Significant correlation of p63 and IRS1 expression was observed in 23 out of 60 HNSCC samples (38%, Fig. 4C and Table S1).

To further investigate the expression levels of p63 and IRS1, we analysed publicly available transcriptome sequencing data of 522 HNSCC patients from the TCGA repository [88]. Overall, the transcript levels of p63 and IRS1 are significantly higher in tumour specimens than in normal samples (Fig. 4D, and 4E). On the basis of their expression levels, for each gene, we stratified tumour patients into two distinct groups, displaying either up-regulation or down-regulation relatively to normal subjects. Notably, we found that 66.2% of tumour samples with p63 up-regulation also exhibited high levels of IRS1 expression. A similar correlation was observed in samples with p63 down-regulation, in which 58% of the patients concomitantly failed to express IRS1.

**Figure 2. p63 binds to the regulatory region of the Irs1 gene.** (A) p63 DNA-binding profiles in the Irs1 locus, obtained in NHKs by ChIP-sequencing (ChIP-seq) using 4A4 and H129 anti-p63 antibodies in two normal human primary keratinocyte cell lines (K1 and K2) [87]. (B) ChIP analysis of p63 occupancy at the regulatory regions of the Irs1 gene. ChIP assays were performed in Fadu HNSCC cells using H129 anti-p63 antibody and control IgGs. PCR validation was performed using primers spanning the p63-binding sites located within the genomic regions identified by ChIP-seq assays. (C) Luciferase reporter assays of Irs1 regulatory regions (left panel). The pGL3 reporter vector (30 ng) and the pRL-CMV-RENilla luciferase plasmid (5 ng) were cotransfected with the empty pcDNA-HA vector or plasmids coding ΔNp63α, ΔNp63β, and ΔNp63γ (150 ng) into the p53 null human H1299 cell line. The luciferase activities of cellular extracts were measured 24 h after transfection. Cellular lysates were also analysed by western blot (right panel). Data are presented as mean ± SD and are representative of three independent experiments.
displayed low levels of IRS1 transcripts (Fig. 4F, p-value= 4.293e-07). Overall, these findings demonstrate that a statistical significant positive association exists between p63 and IRS1 expression in HNSCC patients.

Figure 3. Depletion of p63 reduces the responsiveness of HNSCC cells to ligand stimulation. (A) Fadu cells were transfected with siScr or different p63 (sip63#1, sip63#2, siΔNp63) siRNAs. Forty-eight h after transfection, cells were serum starved for 4 h, and then stimulated with 5 nM IGF1 (upper panel) or 500 ng/ml insulin (lower panel) for 10 min. Protein amounts of p63, IRS1 and p-IRS1 were detected by western blot analysis. β-actin served as loading control. Blots are representative of three individual experiments. (B) Fadu cells were transfected with siScr, sip63#1 and sip63#2, serum starved for 4 h and then stimulated with 5 nM IGF1 for 10 min. Cellular extracts were analysed with the following antibodies: anti-IRS1, anti-p-IRS1, anti-p-AKT, anti-AKT, anti-p-S6 Ribosomal Protein, anti-S6, anti-p44/42 MAPK (p-ERK1/2), anti-ERK1/2, p63 and β-actin as loading control. Blots are representative of three individual experiments. (C) Fadu cells were transfected with siScr or siIRS1 (upper panel) and with sip63#1, ΔNp63, or siScr (lower panel). Forty-eight h after transfection, cells were seeded in 6-cm plates at 500,000/plate and growth was followed until day 6.
DISCUSSION

It has been originally hypothesized that ΔNp63 mainly exerts its oncogenic functions by acting as a dominant negative repressor of the tumour suppressive members of the p53 family, including TAp63. As a consequence of preventing access to their DNA binding sites, ΔNp63 would impinge on the transcription of genes involved in cell cycle control and cell death. In addition, emerging evidence has unveiled key tumour-related signalling pathways that are transcriptionally regulated by ΔNp63, in a p53 independent manner [89]. For instance, by acting in concert with the chromatin remodelling factor ACTL6A, p63 controls chromatin accessibility and functions as a direct transcriptional repressor of the Hippo/YAP regulator WWC1 in SCC [66]. Further-more, ΔNp63 controls a transcriptional program comprising the hyaluronic acid (HA) synthase HAS3 and two hyaluronidase genes, HYAL-1 and HYAL-3, thus sustaining the pro-tumorigenic HA metabolism and signalling [59]. Abraham and collaborators [90] have recently identified components of the transforming growth factor-β signalling and the RHOA GTPase as targets and mediators of ΔNp63-dependent cell proliferation in SCCs.

Our data demonstrate that IRS1 is a direct target of transcriptional activation by ΔNp63 in HNSCC cells. Coherently, ΔNp63 and IRS1 expression patterns are positively correlated in primary tumours, suggesting...
that the interaction of p63 and IRS1 might contribute to the pathogenesis of HNSCC. More broadly, in ΔNp63 overexpressing SSC tumours, unbalanced expression of the TAδNp63/ΔNp63 isoforms may lead to enhanced Igfr1/irs1 transcriptional activation, resulting in augmented protein abundance of IGFR1 and IRS1, which may increase sensitivity of cancer cells to growth factor stimulation (Figure 5). In addition, overexpression of ΔNp63 prevents expression of Igfbp3 thus, ultimately, enhancing circulating IGF-1 (Fig. 5). Thus, the existence of a crosstalk between p63 and the IGF1 system may represent a mechanism by which tumours that overexpress ΔNp63 escape apoptosis and acquire a proliferative advantage.

Elevated levels of IRS1 have been reported to contribute to cancer development and progression [78, 80, 91, 92]. Notably, high expression of IRS1 in breast cancer cells was positively correlated with aberrant phosphorylation of AKT, which was significantly associated with lymph node metastasis [93]. Coherently, we observed reduced ligand-stimulated activation of AKT in p63-depleted cells, implying that reducing the cellular abundance of IRS1 could be a strategy to diminish the mitogenic potential of the IGF system. Acting as an adaptor protein that conveys signals originating from different receptors to multiple downstream signalling molecules, IRS1 represents a potentially relevant predictive clinical biomarkers for cancers susceptible to IGF-IR targeting.

Several reports have showed a correlation between the IGF pathway and HNSCC clinical parameters [80-84]. On the other hand, IGF pathway-related proteins have not been implemented as cancer biomarkers yet, due to the existence of contradictory findings on their prognostic impact. Indeed, negative correlations between levels of IGF1/IGF1R and clinical outcomes have been also reported in HNSCC [94]. Thus, in addition to unveiling alterations within the IGF system in tumours, the identification of alterations outside the IGF axis (e.g. upstream regulators), which may affect the IGF signalling, would be relevant to establish additional predictive markers for patient stratification and clinical management.

The controversial clinical data on the prognostic impact of the IGF system in HNSCC may reflect the high histopathological heterogeneity within this disease that includes tumours arising from various anatomical sites. Whether or not deregulation of the IGF signalling network and the positive regulation of IRS1 by ΔNp63 may have a prognostic significance for HNSCC are still relevant questions in the field, and further studies are needed to clarify these issues.

**MATERIALS AND METHODS**

**Cells and culture conditions**

Neonatal normal human epidermal keratinocytes (NHEKs, Life Technologies) were cultured in EpiLife medium with human keratinocyte growth supplements added (Life Technologies). FaDu (pharynx squamous cell carcinoma), SSC-090 (oral squamous cell carcinoma) and SSC-154 (tongue squamous cell carcinoma) cells were grown in Eagle’s minimum essential medium (EMEM, Lonza, Basel, Switzerland); A253 cells (sub-maxillary salivary gland carcinoma) were cultured in McCoy’s medium (Gibco, Invitrogen); SCC-9 cells (tongue squamous cell carcinoma) were cultured in1:1

---

**Figure 5. A model depicting the crosstalk between p63 and the IGF system.** While the tumour suppressive TAδNp63 isoforms negatively control Igf-1r transcription, the oncogenic ΔNp63 variants induce and repress the expression of the Irs1 and Igfbp3 genes, respectively. In HNSCC cells overexpressing ΔNp63, the transcription of Igf1r would be stimulated as a result of the unbalanced ratio between the TA/ΔN p63 proteins. Aberrant accumulation of IGFR1 and its docking protein IRS1 would enhance signalling activation in response to receptor stimulation. On the other hand, reduced expression levels of Igfbp3 would increase the availability of circulating IGF1 that could further potentiate receptor activation.
mixture of Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F-12 medium (DMEM F12, Gibco, Invitrogen) supplemented with 400 ng/mL hydrocortisone; CAL27 (tongue squamous cell carcinoma) and SCC-104 (oral squamous cell carcinoma) cells were grown in DMEM. All media were supplemented with 10% FBS, 100 U penicillin, and 100 μg/mL streptomycin (Gibco, Life Technologies). All HNSCC cell lines were purchased from ATCC and routinely tested for mycoplasma contaminations.

For p63 siRNA-mediated knockdown, NHEK and HNSCC cells were transfected with the following siRNAs: sip63#1 (SASI_Hs02_00326864) and sip63#2 (SASI_Hs02_00326867) oligos were purchased from Sigma-Aldrich; the sense strand of the siΔNp63 is: 5'-GAAGAAAGGACACGCAGCATTTG-3'. The Negative Control siRNA (Qiagen, AATTCTCCGAACGCTGTCAGTGC-3') was used as a silencing control. All transfections were performed using the Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to manufacturer's protocols.

RNA sequencing

RNA sequencing was performed as previously described [95]. Briefly, total RNA was extracted using a mirVana miRNA isolation kit (Thermo Fisher). rRNA was removed from each RNA extraction before proceeding with RNA seq library construction. Sequencing was performed on a SOLiD sequencer 5500XL (Applied Biosystems) with 75-base-pair single-end reads by Genomnica s.r.l. (Milan, Italy). Sequencing reads in SOLID “xsq” format were mapped to the hg19 genome built and analysed with the Lifetech Lifescope 2.5.1 Whole Transcriptomic analysis pipeline with the Integromics Seqsolve software and proprietary Genomnica procedures.

Real-time qPCR

Total RNA was extracted by the RNAeasy kit (Qiagen, Hilden, Germany). Total RNA (500ng) was used for reverse transcription using GoScript Reverse Transcription System kit (Promega, Fitchburg, WI, USA) following the manufacturer's instructions. Human Tbp mRNA was used as housekeeping gene for quantity normalization. qRT-PCR was performed using the Platinum SYBR Green qPCR SuperMix UDG (Invitrogen), using the following primer pairs: Irs1 5'-CTCAACTGGACATCACAGCAG-3' (sense) and 5'-AGTGCTTAGTGGTGAAATCATAG-3' (antisense); TAp63 5'-TCAGAAGATGTTGGCAGAACAC-3' (sense) and 5'-GGTCAGGAGCCAGCAGTGCG-3' (antisense); ΔNp63 5'-GAAGAAGGACACGCAGCATTTG-3' (sense) and 5'-GGCGACTGGTGGACGAGGA-3' (antisense). The PCR was monitored by a melting curve protocol according to the specifications of the ABI 7500 instrument (Applied Biosystems). Relative quantification of gene expression was calculated according to the 2^-ΔΔCt method. IRS1 expression was normalized on Tbp housekeeper.

Western blot analysis

Cells were lysed in SDS lysis buffer (100 mM Tris pH 8.8, 1% SDS, 5 mM EDTA, 20 mM DTT, and 2 mM AEBSF). Total protein extracts were resolved in SDS polyacrylamide gel and blotted onto a Hybond PVDF membrane (GE Healthcare, Chicago, IL, USA). After being blocked with PBST 5% non-fat dry milk (Bio-Rad), membranes were incubated over night with primary antibodies at +4°C, washed and hybridized for 1 h at room temperature using the appropriate horse-radish peroxidase-conjugated secondary antibody (rabbit and mouse, Bio-Rad, Hercules, California, USA). Detection was performed with the ECL chemiluminescence kit (Perkin Elmer, Waltham, Massachusetts, USA). The following antibodies were used: anti-IRS1 (D32G12, Cell Signaling), anti-p63 (clone 4A4, Santa Cruz Biotechnology), anti-p-IRS1 (Ser612, clone C15H5, Cell Signaling), anti-p-AKT (Ser473, clone D9E, Cell Signaling), anti-AKT (clone #9272, Cell Signaling), anti-p-s6 Ribosomal Protein (Ser235/236, clone #2211, Cell Signaling), anti-S6 (Clone 5G10, Cell Signaling), anti-p-ERK1/2 (Thr202/Tyr204, Clone 5G10, Cell Signaling), anti-p-ERK1/2 (Clone 137F5, Cell Signaling).

Chromatin immunoprecipitation assay

Fadu cells were used for ChIP assay. Cells were collected, fixed in 1% formaldehyde, and subjected to sonication for DNA shearing. The ChIP assay was performed with an anti-p63 antibody (H129, Santa Cruz Biotechnology) or unspecific immunoglobulin G (IgG) (Invitrogen) using a ChIP assay Kit (Invitrogen). PCR validation was performed using primers spanning the p63-binding sites located within the genomic regions identified by ChIP-seq assays.

Luciferase assay

For luciferase assays, a total of 1.2×10⁶ H1299 cells were seeded in 12-well dishes 24 h before transfection. In total, 30 ng of pGL3 reporter vector, 5 ng of pRL-CMV-Renilla luciferase vector (Promega) and 150 ng of HA-ΔNp63α expression vectors or empty pcDNA-HA vector (as a control) were cotransfected using the Effectene transfection reagent according to the manufacturer's instructions (Qiagen). The luciferase activities of cellular extracts were measured 24 h after trans-
fection using a Dual Luciferase Reporter Assay System (Promega). The light emission was measured over 10 sec using a Lumat LB9507 luminometer (EG&GBerthold). The transfection efficiency was normalized to Renilla luciferase activity. The p63 RE was mutated by site-directed mutagenesis using the forward primer: 5’-ATAAGGCCTTCTGTTCCGAGCACGGCTGCCTCGGAACAGGAGG-3’ and reverse primer: 5’-GTTGGTTCACACGGCTGCCTCGGAACAGGAAGGCCCTTAT-3’.

Human HNSCC tumour tissues

Tissue arrays including paraffin-embedded HNSCC (n=60), adenoid cystic carcinomas (n=7), adeno-carcinomas (n=1), mucoepidermoid carcinomas (n=1), and normal tissues. (n=10) were purchased from US Biomax, Inc. (Rockville, MD). Samples were deparaffinized and rehydrated in 1x PBS for 10 min. Tissue sections were stained with anti-p63 (clone 4A4, Ventana) and IRS1 (Clone EP263Y, Abcam) antibodies. Immunohistochemistry (IHC) scoring was performed by two independent pathologists. The percentage of positive cells was rated as follows: 0, negative; 1, 1–25% positive cells; 2, 26–50% positive cells; 3, 51–75% positive cells; and 4, >75% positive cells. The staining intensity was scored as 0, negative; 1, weak; 2, moderate; and 3, intensive. For both stainings, the scores for the percentage of positive cells and those for the expression intensities were combined to calculate immunoreactive scores (IRSs) that are summarised in Table S1. According to the IRS, we grouped patients into five groups: 0 (no expression), 0.5 (low expression), 1 (moderate expression), 1.5-2 (high expression), and 2.5-3 (very high expression). Non squamous cell carcinomas of the head and neck were excluded from the analysis.

Computational methods

Publicly available gene expression data from TCGA were downloaded from the Genomic Data Commons (GDC) Data Portal and pre-processed via the TCGAbiolinks R package [96]. Harmonized and normalized RPKM data from GDC was downloaded for Head and Neck Squamous Cell Carcinomas (TCGA-HNSC).

RPKM distributions for each of the genes of interest have been analyzed either for tumor and normal samples in the HNSC cohort. A discrimination cutpoint between tumor and normal expression distributions either for TP63 and IRS1 has been detected using OptimalCutpoints R package [97]. The identified optimal cutoffs represent the RPKM values that maxi-mize the separation of gene expression distributions in tumor and normal samples. Data mining, statistical tests (Wilcoxon and Fisher’s exact tests) and plots on TCGA gene expression data were performed in R.

Statistical analysis

The significance of differences between two experimental groups was calculated using the two-tailed Student’s t-test. Values with P<0.05 were considered significant.

CONFLICTS OF INTEREST

The authors of this manuscript declare no conflicts of interest.

FUNDING

This work was partially supported by “Mission Sustainability” 2017 (“Head and neck squamous cell tumours: the identification of new biomarkers”) to FB, by MFAG 2014 Id.15523 to AP, by the Medical Research Council (to GM), Associazione Italiana per la Ricerca contro il Cancro (AIRC) to GM IG#20473 (2018-2022), Fondazione Luigi Maria Monti IDIRCCS (RC to EC), Ministry of Health Italy-China cooperation grant. Work has been also supported by Regione Lazio through Lazio Innova Progetto Gruppo di Ricerca n 85-2017-14986.

REFERENCES

1. Lin MC, Chien PH, Wu HY, Chen ST, Juan HF, Lou PJ, Huang MC. C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer. Oncogene. 2018; 37:5780–93. https://doi.org/10.1038/s41388-018-0375-0

2. Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, Mueller SC, Agostino SD, Blandino G, et al. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ. 2016; 23:1615–27. https://doi.org/10.1038/cdd.2016.48

3. Amelio I, Knight RA, Lisatsa A, Melino G, Antonov AV. p53MutaGene: an online tool to estimate the effect of p53 mutational status on gene regulation in cancer. Cell Death Dis. 2016; 7:e2148. https://doi.org/10.1038/cddis.2016.42

4. Alexandrova EM, Moll UM. Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy. Cell
1. Ghosh S, Salot S, Sengupta S, Navalkar A, Ghosh D, Jacob R, Das S, Kumar R, Jha NN, Sahay S, Mehra S, Mohite GM, Ghosh SK, et al. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis. Cell Death Differ. 2017; 24:1784–98. https://doi.org/10.1038/cdd.2017.105

2. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005; 7:363–73. https://doi.org/10.1016/j.ccr.2005.02.019

3. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annichiarico-Petrizelli M, Antonov AV, Arama E, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018; 25:486–541. https://doi.org/10.1038/s41418-017-0012-4

4. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H, Lena AM, Candi E, Terrinoni A, Catani MV, Oren M, Melino G, Kramer PH, et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005; 24:2458–71. https://doi.org/10.1038/sj.emboj.7600708

5. Inoue S, Tomasin R, Rufini A, Elia AJ, Agostini M, Amelio I, Cescon D, Dinsdale D, Zhou L, Harris IS, Lac S, Silvester J, Li WY, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility. Proc Natl Acad Sci USA. 2014; 111:1843–48. https://doi.org/10.1073/pnas.1323416111

6. Levine AJ, Tomasin R, McKeon FD, Mak TW, Melino G. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol. 2011; 12:259–65. https://doi.org/10.1038/nrm3086

7. Marino A, Rotblat B, Sbarrato T, Niklison-Chirou MV, Knight JR, Dudek K, Jones C, Bushell M, Knight RA, Amelio I, Willis AE, Melino G. TAp73 contributes to the oxidative stress response by regulating protein synthesis. Proc Natl Acad Sci USA. 2018; 115:6219–24. https://doi.org/10.1073/pnas.1718531115

8. Baldelli S, Ciriolo MR. Altered S-nitrosylation of p53 is responsible for impaired antioxidant response in skeletal muscle during aging. Aging (Albany NY). 2016; 8:3450–67. https://doi.org/10.18632/aging.101139

9. Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Lett. 2018; 592:2083–97. https://doi.org/10.1002/1873-3468.13057

10. Guo X, Keyes WM, Papazoglou C, Zuber J, Li W, Lowe SW, Vogel H, Mills AA. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol. 2009; 11:1451–57. https://doi.org/10.1038/ncb1988

11. Regina C, Compagnone M, Peschiaroli A, Lena AM, Melino G, Candi E. ΔNp63α modulates histone methyl transferase SETDB1 to transcriptionally repress target genes in cancers. Cell Death Discov. 2016; 2:16015. https://doi.org/10.1038/cddiscovery.2016.15

12. Rivetti di Val Cervo P, Lena AM, Niccolos M, Rossi S, Mancini M, Zhou H, Saintigny G, Dellambra E, Odoriso T, Mahé C, Calin GA, Candi E, Melino G. p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci USA. 2012; 109:1133–38. https://doi.org/10.1073/pnas.1112257109

13. Rufini A, Niklison-Chirou MV, Inoue S, Tomasin R, Harris IS, Marino A, Federici M, Dinsdale D, Knight RA, Melino G, Mak TW. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev. 2012; 26:2009–14. https://doi.org/10.1101/gad.197640.112

14. Artigas N, Gámez B, Cabillos-Rojas M, Sánchez-de Diego C, Valer JA, Pons G, Rosa JL, Ventura F. p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation. Cell Death Differ. 2017; 24:2022–31. https://doi.org/10.1038/cdd.2017.113

15. Belle JI, Petrov JC, Langlais D, Robert F, Cencic R, Shen S, Pelletier J, Gros P, Nijink A. Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance. Cell Death Differ. 2016; 23:759–75. https://doi.org/10.1038/cdd.2015.140

16. Agostini M, Romeo F, Inoue S, Niklison-Chirou MV, Elia AJ, Dinsdale D, Morone N, Knight RA, Mak TW, Melino G. Metabolic reprogramming during neuronal differentiation. Cell Death Differ. 2016; 23:1502–14. https://doi.org/10.1038/cdd.2016.36

17. Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V. p53 on the crossroad between regeneration and cancer. Cell Death Differ. 2017; 24:8–14. https://doi.org/10.1038/cdd.2016.117

18. Di Franco S, Sala G, Todaro M. p63 role in breast cancer. Aging (Albany NY). 2016; 8:2256–57. https://doi.org/10.18632/aging.101042

19. Gross A, Zaltsman Y, Maryanovich M. The ATM-BID pathway plays a critical role in the DNA damage response by regulating mitochondria metabolism. Cell

www.aging-us.com 4233 AGING
24. Giacomello M, Pellegrini L. The coming of age of the mitochondria-ER contact: a matter of thickness. Cell Death Differ. 2016; 23:1417–27. https://doi.org/10.1038/cdd.2016.52

25. Kagan VE, Jiang J, Huang Z, Tyurina YY, Desbourdes C, Cottet-Rousselle C, Dar HH, Verma M, Tyurin VA, Kapralov AA, Cheikhi A, Mao G, Stolz D, et al. NDK-D (NM23-H4)-mediated externalization of cardiolipin enables elimination of depolarized mitochondria by mitophagy. Cell Death Differ. 2016; 23:1140–51. https://doi.org/10.1038/cdd.2015.160

26. Martin-Lopez M, Maeso-Alonso L, Fuertes-Alvarez S, Balboa D, Rodriguez-Cortez V, Weltner J, Diez-Prieto I, Davis A, Wu Y, Otonkoski T, Flores ER, Menéndez P, Marques MM, Marin MC. p73 is required for appropriate BMP-induced mesenchymal-to-epithelial transition during somatic cell reprogramming. Cell Death Dis. 2017; 8:e3034. https://doi.org/10.1038/cddis.2017.432

27. Lovat PE, Ranalli M, Annichiarico-Petruzelli M, Bernassola F, Piacentini M, Malcolm AJ, Pearson AD, Melino G, Redfern CP. Effector mechanisms of ferretin-induced apoptosis in neuroblastoma. Exp Cell Res. 2000; 260:50–60. https://doi.org/10.1006/excr.2000.4988

28. Tóth B, Garabuzci E, Sarang Z, Vereb G, Vámosi G, Aeschlimann D, Blaskó B, Bécsi B, Erdődi F, Lacy-Hulbert A, Zhang A, Falasca L, Birge RB, et al. Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. J Immunol. 2009; 182:2084–92. https://doi.org/10.4049/jimmunol.0803444

29. Zhao J, Yin M, Deng H, Jin FQ, Xu S, Lu Y, Mastrangelo MA, Luo H, Jin ZG. Cardiac Gab1 deletion leads to dilated cardiomyopathy associated with mitochondrial damage and cardiomyocyte apoptosis. Cell Death Differ. 2016; 23:695–706. https://doi.org/10.1038/cdd.2015.143

30. Van Nostrand JL, Bowen ME, Vogel H, Barna M, Attardi LD. The p53 family members have distinct roles during mammalian embryonic development. Cell Death Differ. 2017; 24:575–79. https://doi.org/10.1038/cdd.2016.128

31. Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, et al. p53 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016; 8:345–65. https://doi.org/10.18632/aging.100898

32. Tak H, Eun JW, Kim J, Park SJ, Kim C, Ji E, Lee H, Kang H, Cho DH, Lee K, Kim W, Nam SW, Lee EK. T-cell-restricted intracellular antigen 1 facilitates mitochondrial fragmentation by enhancing the expression of mitochondrial fission factor. Cell Death Differ. 2017; 24:49–58. https://doi.org/10.1038/cdd.2016.90

33. Dey-Rao R, Sinha AA. Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo. Genes Immun. 2016; 17:30–45. https://doi.org/10.1038/gene.2015.48

34. Gianfrancesco MA, Balzer L, Taylor KE, Trupin L, Nititham J, Seldin MF, Singer AW, Criswell LA, Barcellos LF. Genetic risk and longitudinal disease activity in systemic lupus erythematosus using targeted maximum likelihood estimation. Genes Immun. 2016; 17:358–62. https://doi.org/10.1038/gene.2016.33

35. Greschik H, Duteil D, Messaddeq N, Willmann D, Arrigoni L, Sum M, Jung M, Metzger D, Manke T, Günther T, Schüle R. The histone code reader Spin1 controls skeletal muscle development. Cell Death Dis. 2017; 8:e3173. https://doi.org/10.1038/cddis.2017.468

36. Hussman JP, Beecham AH, Schmidt M, Martin ER, McCauley JL, Vance JM, Haines JL, Pericak-Vance MA. GWAS analysis implicates NF-kB-mediated induction of inflammatory T cells in multiple sclerosis. Genes Immun. 2016; 17:305–12. https://doi.org/10.1038/gene.2016.23

37. Salsman J, Rapkin LM, Margam NN, Duncan R, Bazzett-Jones DP, Dellaire G. Myogenic differentiation triggers PML nuclear body loss and DAXX relocalization to chromocentres. Cell Death Dis. 2017; 8:e2724. https://doi.org/10.1038/cddis.2017.151

38. Baraibar MA, Hyzewicz J, Rogowska-Wrzesinska A, Bulteu AL, Prip-Buus C, Butler-Browne G, Friguet B. Impaired energy metabolism of senescent muscle satellite cells is associated with oxidative modifications of glycolytic enzymes. Aging (Albany NY). 2016; 8:3375–89. https://doi.org/10.18632/aging.101126

39. Brzeszczyńska J, Johns N, Schilb A, Degen S, Degen M, Langen R, Schols A, Glass DJ, Roubenoff R, Greig CA, Jacoby C, Fearon KC, Ross JA. Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging (Albany NY). 2016; 8:1690–702. https://doi.org/10.18632/aging.101006
40. Choi JY, Hwang CY, Lee B, Lee SM, Bahn YJ, Lee KP, Kang M, Kim YS, Woo SH, Lim JY, Kim E, Kwon KS. Age-associated repression of type 1 inositol 1, 4, 5-triphosphate receptor impairs muscle regeneration. Aging (Albany NY). 2016; 8:2062–80. https://doi.org/10.18632/aging.101039

41. Fiacco E, Castagnetti F, Bianconi V, Madaro L, De Bardi M, Nazio F, D’Amico A, Bertini E, Cecconi F, Puri PL, Latella L. Autophagy regulates satellite cell ability to regenerate normal and dystrophic muscles. Cell Death Differ. 2016; 23:1839–49. https://doi.org/10.1038/cdd.2016.70

42. Honrath B, Matschke L, Meyer T, Magerhans L, Perocchi F, Ganjam GK, Zischka H, Krasel C, Gerdung A, Bakker BM, Bünnemann M, Strack S, Decher N, et al. SK2 channels regulate mitochondrial respiration and mitochondrial Ca2+ uptake. Cell Death Differ. 2017; 24:761–73. https://doi.org/10.1038/cdd.2017.2

43. Kaufman DM, Wu X, Scott BA, Itani OA, Van Gilst MR, Bruce JE, Crowder CM. Ageing and hypoxia cause protein aggregation in mitochondria. Cell Death Differ. 2017; 24:1730–38. https://doi.org/10.1038/cdd.2017.101

44. Pinto M, Pickrell AM, Wang X, Bachman SR, Yu A, Hida A, Dillon LM, Morton PD, Malek TR, Williams SL, Moraes CT. Transient mitochondrial DNA double strand breaks in mouse cause accelerated aging phenotypes in a ROS-dependent but p53/p21-independent manner. Cell Death Differ. 2017; 24:288–99. https://doi.org/10.1038/cdd.2016.123

45. Qi Y, Liu H, Daniels MP, Zhang G, Xu H. Loss of Drosophila i-AAA protease, dYME1L, causes abnormal mitochondria and apoptotic degeneration. Cell Death Differ. 2016; 23:291–302. https://doi.org/10.1038/cdd.2015.94

46. Kaestner L, Minetti G. The potential of erythrocytes as cellular aging models. Cell Death Differ. 2017; 24:1475–77. https://doi.org/10.1038/cdd.2017.100

47. Kanemaru K, Nakamura Y, Totoki K, Fukuyama T, Shoji M, Kaneko H, Shiratori K, Yoneda A, Inoue T, Iwakura Y, Kabashima K, Fukami K. Phospholipase Cδ1 regulates p38 MAPK activity and skin barrier integrity. Cell Death Differ. 2017; 24:1079–90. https://doi.org/10.1038/cdd.2017.56

48. Fortini P, Ferretti C, Iorio E, Cagnin M, Garribba L, Pietraforte D, Falchi M, Pascucci B, Baccarin S, Morani F, Phadnagam S, De Luca G, Isidoro C, Dogliotti E. The fine tuning of metabolism, autophagy and differentiation during in vitro myogenesis. Cell Death Dis. 2016; 7:e2168. https://doi.org/10.1038/cddis.2016.50

49. Lee SJ, Hwang J, Jeong HJ, Yoo M, Go GY, Lee JR, Leem YE, Park JW, Seo DW, Kim YK, Hahn MJ, Han JW, Kang JS, Bae GU. PKN2 and Cdo interact to activate AKT and promote myoblast differentiation. Cell Death Dis. 2016; 7:e2431. https://doi.org/10.1038/cddis.2016.296

50. Li G, Luo W, Abdalla BA, Ouyang H, Yu J, Hu F, Nie Q, Zhang X. miRNA-223 upregulated by MYOD inhibits myoblast proliferation by repressing IGF2 and facilitates myoblast differentiation by inhibiting ZEB1. Cell Death Dis. 2017; 8:e3094. https://doi.org/10.1038/cddis.2017.479

51. Palazzo E, Kellett MD, Catisson C, Bible PW, Bhattacharya S, Sun HW, Gormley AC, Yuspa SH, Morasso MI. A novel DLX3-PKC integrated signaling network drives keratinocyte differentiation. Cell Death Differ. 2017; 24:717–30. https://doi.org/10.1038/cddis.2017.5

52. Shao AW, Sun H, Geng Y, Peng Q, Wang P, Chen J, Xiong T, Cao R, Tang J. Bclaf1 is an important NF-κB signaling transducer and C/EBPβ regulator in DNA damage-induced senescence. Cell Death Differ. 2016; 23:865–75. https://doi.org/10.1038/cdd.2015.150

53. Tajhya RB, Hu X, Tanner MR, Huq R, Kongchan N, Neilson JR, Rodney GG, Harrigan FT, Timchenko LT, Beeton C. Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell Death Dis. 2016; 7:e2426. https://doi.org/10.1038/cddis.2016.324

54. Wei X, Li H, Yang J, Hao D, Dong D, Huang Y, Lan X, Plath M, Lei C, Lin F, Bai Y, Chen H. Circular RNA profiling reveals an abundant circLM07 that regulates myoblasts differentiation and survival by sponging miR-378a-3p. Cell Death Dis. 2017; 8:e3153. https://doi.org/10.1038/cddis.2017.541

55. Zhai L, Wu R, Han W, Zhang Y, Zhu D. miR-127 enhances myogenic cell differentiation by targeting S1PR3. Cell Death Dis. 2017; 8:e2707. https://doi.org/10.1038/cddis.2017.128

56. De Laurenzi V, Melino G. Evolution of functions within the p53/p63/p73 family. Ann N Y Acad Sci. 2000; 926:90–100. https://doi.org/10.1111/j.1749-6632.2000.tb05602.x

57. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005; 6:328–40. https://doi.org/10.1038/nrm1619

58. Candi E, Terrinoni A, Rufini A, Chikh A, Lena AM, Suzuki Y, Sayan BS, Knight RA, Melino G. p63 is upstream of IKKα in epidermal development. J Cell Sci. 2006; 119:4617–22.
59. Compagnone M, Gatti V, Presutti D, Ruberti G, Fierro C, Markert EK, Vosden KH, Zhou H, Mauriello A, Anemone L, Bongiorno-Borbone L, Melino G, Peschiarioli A. ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis. Proc Natl Acad Sci USA. 2017; 114:13254–59. https://doi.org/10.1073/pnas.1711777114

60. Novelli F, Lena AM, Panatta E, Nasser W, Shalom-Feuerstein R, Candi E, Melino G. Allele-specific silencing of EEC p63 mutant R304W restores p63 transcriptional activity. Cell Death Dis. 2016; 7:e2227. https://doi.org/10.1038/cddis.2016.118

61. Candi E, Amelio I, Agostini M, Melino G. MicroRNAs and p63 in epithelial stemness. Cell Death Differ. 2015; 22:12–21. https://doi.org/10.1038/cdd.2014.113

62. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A, De Laurenzi V, Spagnoli LG, Catani MV, Ramadan S, Knight RA, Melino G. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ. 2006; 13:1037–47. https://doi.org/10.1038/sj.cdd.4401926

63. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatili L, Ibrahim T, Amadori D, Kannan N, et al. ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014; 16:1004–15, 1–13. https://doi.org/10.1038/ncb3040

64. Memmi EM, Sanarico AG, Giacobbe A, Peschiarioli A, Frezza V, Cicalese A, Pisati F, Tosoni D, Zhou H, Tonon G, Antonov A, Melino G, Pelicci PG, Bernassola F. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signalling. Proc Natl Acad Sci USA. 2015; 112:3499–504. https://doi.org/10.1073/pnas.1500762112

65. Cancer Genome Atlas N, and Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517:576–82. https://doi.org/10.1038/nature14129

66. Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H, Rajagopal J, Ramaswamy S, Ellisén LW. ACTL6A is co-amplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis. Cancer Cell. 2017; 31:35–49. https://doi.org/10.1016/j.ccell.2016.12.001

67. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, et al, and Cancer Genome Atlas Research Network. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports. 2018; 23:194–212.e6. https://doi.org/10.1016/j.celrep.2018.03.063

68. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisén LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 2006; 9:45–56. https://doi.org/10.1016/j.ccr.2005.12.013

69. Yang X, Lu H, Yan B, Romano RA, Bian Y, Friedman J, Duggal P, Allen C, Chuang R, Ehsanian R, Si H, Sinha S, Van Waes C, Chen Z. ΔNp63 versatiley regulates a Broad NF-kB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 2011; 71:3688–700. https://doi.org/10.1158/0008-5472.CAN-10-3445

70. Lo Muzio L, Santarelli A, Caltabiano R, Rubini C, Pieramici T, Trevisiol L, Carinci F, Leonardi R, De Lillo A, Lanzafame S, Bufò P, Piattielli A. p63 over-expression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol. 2005; 36:187–94. https://doi.org/10.1016/j.humpath.2004.12.003

71. Chen Y, Li Y, Peng Y, Zheng X, Fan S, Yi Y, Zeng P, Chen H, Kang H, Zhang Y, Xiao ZX, Li C. ΔNp63α down-regulates c-Myc modulator MM1 via E3 ligase HERC3 in the regulation of cell senescence. Cell Death Differ. 2018; 25:2118–29. https://doi.org/10.1038/s41418-018-0132-5

72. Si H, Lu H, Yang X, Mattox A, Jang M, Bian Y, Sano E, Viadiu H, Yan B, Yao C, Ng S, Lee SK, Romano RA, et al. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-kB cRELa interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer. Oncogene. 2016; 35:5781–94. https://doi.org/10.1038/onc.2016.112

73. Carvalho E, Jansson PA, Axelsen M, Eriksson JW, Huang X, Groop L, Rondinone C, Sjöström L, Smith U. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J. 1999; 13:2173–78. https://doi.org/10.1096/fasebj.13.15.2173

74. Zhou Y, Zhang Z, Wang N, Chen J, Zhang X, Guo M, John Zhong L, Wang Q. Suppressor of cytokine signalling-2 limits IGF1R-mediated regulation of epithelial-mesenchymal transition in lung adeno-carcinoma. Cell Death Dis. 2018; 9:429. https://doi.org/10.1038/s41419-018-0457-5

75. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE,
Nicholson RI, Carboni J, Gottardis M, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008; 68:10238–46. https://doi.org/10.1158/0008-5472.CAN-08-2755

76. Jameson MJ, Beckler AD, Taniguchi LE, Allak A, Vanwagner LB, Lee NG, Thomsen WC, Hubbard MA, Thomas CY. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther. 2011; 10:2124–34. https://doi.org/10.1158/1535-7163.MCT-11-0294

77. Chang Q, Li Y, White MF, Fletcher JA, Xiao S. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res. 2002; 62:6035–38.

78. Koda M, Sulikowska M, Kanczuga-Koda L, Sulikowski S. Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J Clin Pathol. 2005; 58:645–49. https://doi.org/10.1136/jcp.2004.022590

79. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor I and prostate cancer risk: a prospective study. Science. 1998; 279:563–66. https://doi.org/10.1126/science.279.5350.563

80. Luo J, Wen Q, Li J, Xu L, Chu S, Wang W, Shi L, Xie G, Huang D, Fan S. Increased expression of IRS-1 is associated with lymph node metastasis in nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2014; 7:6117–24.

81. Dale OT, Aleksic T, Shah KA, Han C, Mehanna H, Rapoza DC, Sheard JD, Goodyear P, Upile NS, Robinson M, Jones TM, Winter S, Macaulay VM. IGFR-1 expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer. Carcinogenesis. 2015; 36:648–55. https://doi.org/10.1093/carcin/bgv053

82. Lara PC, Bordón E, Rey A, Moreno M, Lloret M, Henríquez-Hernández LA. IGFR-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma. Oral Oncol. 2011; 47:615–19. https://doi.org/10.1016/j.oraloncology.2011.05.005

83. Wu X, Zhao H, Do KA, Johnson MM, Dong Q, Hong WK, Spitz MR. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res. 2004; 10:3988–95. https://doi.org/10.1158/1078-0432.CCR-03-0762

84. Sun JM, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, Baek JH, Park K, Ahn MJ. Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. Oral Oncol. 2011; 47:714–19. https://doi.org/10.1016/j.oraloncology.2011.06.007

85. Nahor I, Abramovitch S, Engeland K, Werner H. The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res. 2005; 15:388–96. https://doi.org/10.1016/j.ghir.2005.07.005

86. Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res. 2005; 65:2314–20. https://doi.org/10.1158/0008-5472.CAN-04-3449

87. Kouwenhoven EN, van Heeringen SJ, Tena JJ, Oti M, Dutilh BE, Alonso ME, de la Calle-Mustienes E, Smeenk L, Rinne T, Parsaaulian L, Bolat E, Jurgenlenaitė R, Huynen MA, et al. Genome-wide profiling of p63 DNA-binding sites identifies an element that regulates gene expression during limb development in the 7q21 SHFM1 locus. PLoS Genet. 2010; 6:e1001065. https://doi.org/10.1371/journal.pgen.1001065

88. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM, and Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45:1113–20. https://doi.org/10.1038/ng.2764

89. Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat. 2014; 35:702–14. https://doi.org/10.1002/humu.22523

90. Abraham CG, Ludwig MP, Andryszik Z, Pandey A, Joshi M, Galbraith MD, Sullivan KD, Espinosa JMY. ΔNp63α Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Reports. 2018; 24:3224–36. https://doi.org/10.1016/j.celrep.2018.08.058

91. Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res. 1996; 56:3391–94.

92. Xu H, Lee MS, Tsai PY, Adler AS, Curry NL, Challa S, Freinkman E, Hitchcock DS, Copps KD, White MF, Bronson RT, Marcotrigiano M, Wu Y, et al. Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis. Proc Natl Acad Sci USA. 2018; 115:4228–33.
93. Luo J, Feng J, Wen Q, Qoyawayma C, Wang W, Chen L, Lu J, Zhan Y, Xu L, Zang H, Fan S, Chu S. Elevated expression of IRS-1 associates with phosphorylated Akt expression and predicts poor prognosis of breast invasive ductal carcinoma. Hum Pathol. 2018; 79:9–17. https://doi.org/10.1016/j.humpath.2018.03.003

94. Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, Buhren BA, Flehmig B, Budach W, Knoefel WT, Bojar H, Prisack HB, Steinbach G, Shukla V, et al. Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res. 2011; 16:451–56. https://doi.org/10.1186/2047-783X-16-10-451

95. Smirnov A, Lena AM, Cappello A, Panatta E, Anemona L, Bischetti S, Annicchiarico-Petruzzelli M, Mauriello A, Melino G, Candi E. ZNF185 is a p63 target gene critical for epidermal differentiation and squamous cell carcinoma development. Oncogene; 2018. https://doi.org/10.1038/s41388-018-0509-4. Epub ahead of print

96. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G, Noushmehr H. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016; 44:e71. https://doi.org/10.1093/nar/gkv1507

97. Lopez-Raton M, Cadarso-Suarez C, Rodriguez-Alvarez MX, Gude-Sampedro F. Optimal cutpoints: an R package for selecting optimal cutpoints in diagnostic tests. J Stat Softw. 2014; 61:1–36. https://doi.org/10.18637/jss.v061.i08
**Supplementary Material**

**Supplementary Figure 1.** Effect of distinct siRNAs against p63 on IRS1 expression.

**Supplementary Table S1.** Clinical features of HNSCC patients (as provided by Biomax), whose tumour samples were analysed for p63/IRS1 expression levels.

| Patient sample | p63 Score | IRS1 Score | Organ       | PATHOLOGY DIAGNOSIS                  | GRADE | STAGE | TNM     | TYPE | SEX | AGE |
|----------------|-----------|------------|-------------|-------------------------------------|-------|-------|---------|------|-----|-----|
| A1             | 0         | 0.5        | Lip         | Squamous cell carcinoma of right lower lip | 1     | IIA   | T2N0M0  | Malignant | F   | 60  |
| A2             | 2         | 1          | Nose        | Squamous cell carcinoma of right nasal cavity | 1     | I     | T1N0M0  | Malignant | F   | 45  |
| A3             | 0.5       | 1          | Tongue      | Squamous cell carcinoma               | 1     | III   | T3N1M0  | Malignant | M   | 28  |
| A4             | 0.5       | 0.5        | Tongue      | Squamous cell carcinoma               | 1     | II    | T2N0M0  | Malignant | M   | 42  |
| A5             | 1         | 1          | Tongue      | Squamous cell carcinoma               | 1     | III   | T2N0M0  | Malignant | M   | 50  |
| A6             | 1.5       | 0.5        | Larynx      | Squamous cell carcinoma               | 1     | II    | T2N0M0  | Malignant | M   | 45  |
| A7             | 0.5       | 1          | Larynx      | Squamous cell carcinoma               | 1     | IVA   | T4N0M0  | Malignant | M   | 49  |
| A8             | 1.5       | 1          | Larynx      | Squamous cell carcinoma               | 1     | II    | T2N0M0  | Malignant | M   | 66  |
| A9             | 0.5       | 1.5        | Larynx      | Squamous cell carcinoma               | 1     | IVA   | T4N0M0  | Malignant | M   | 47  |
| A10            | 0.5       | 0.5        | Larynx      | Squamous cell carcinoma               | –     | IV    | T4N0M0  | Malignant | M   | 60  |
| B1             | 0.5       | 0.5        | Larynx      | Squamous cell carcinoma               | 1     | II    | T2N0M0  | Malignant | M   | 51  |
| B2             | 1.5       | 1.5        | Larynx      | Squamous cell carcinoma               | 2     | IIIB  | T2N1M0  | Malignant | M   | 59  |
| B3             | 0.5       | 2          | Cheek       | Squamous cell carcinoma of left cheek | 1     | II    | T2N0M0  | Malignant | M   | 37  |
| B4             | 3         | 3          | Face        | Squamous cell carcinoma               | 1     | III   | T3N0M0  | Malignant | M   | 83  |
| B5             | 1.5       | 1          | Face        | Squamous cell carcinoma of mandible   | 1     | III   | T3N0M0  | Malignant | M   | 57  |
| B6             | 0         | 1          | Cheek       | Squamous cell carcinoma of buccal region | 1     | II    | T2N0M0  | Malignant | M   | 70  |
| B7             | 2         | 0.5        | Oral cavity | Squamous cell carcinoma of gingiva    | 1     | III   | T3N0M0  | Malignant | M   | 60  |
| B8             | 0.5       | 1          | Oral cavity | Squamous cell carcinoma of left maxillary sinus | 1     | III   | T3N0M0  | Malignant | M   | 55  |
| B9             | 2.5       | 0.5        | Oral cavity | Squamous cell carcinoma of upper jaw  | 1     | IV    | T4N0M0  | Malignant | M   | 40  |
| B10            | 1.5       | 1          | Tongue      | Squamous cell carcinoma               | 1     | II    | T2N0M0  | Malignant | M   | 58  |
| C1             | 3         | 0          | Larynx      | Squamous cell carcinoma               | 2     | IIIB  | T2N1M0  | Malignant | M   | 45  |
| C2             | 1.5       | 0.5        | Larynx      | Squamous cell carcinoma               | 2     | IV    | T4N0M0  | Malignant | M   | 50  |
| C3             | 2.5       | 0          | Larynx      | Squamous cell carcinoma               | 2     | IV    | T4N0M0  | Malignant | M   | 54  |
| C4             | 0         | 1          | Larynx      | Squamous cell carcinoma               | 2     | II    | T2N0M0  | Malignant | M   | 64  |
| C5             | 3         | 1          | Face        | Squamous cell carcinoma of left face   | 2     | I     | T1N0M0  | Malignant | M   | 65  |
| C6             | 2.5       | 0          | Larynx      | Squamous cell carcinoma               | 2     | IVA   | T4N0M0  | Malignant | M   | 49  |
| C7             | 1         | 0          | Larynx      | Squamous cell carcinoma               | 3     | I     | T1N0M0  | Malignant | M   | 48  |
| C8             | 0         | 1          | Larynx      | Squamous cell carcinoma               | 2     | II    | T2N0M0  | Malignant | M   | 55  |
| C9             | 2         | 0.5        | Larynx      | Squamous cell carcinoma               | 2     | III   | T3N0M0  | Malignant | M   | 72  |
| C10            | 1         | 0          | Larynx      | Squamous cell carcinoma               | 3     | IV    | T4N0M0  | Malignant | M   | 59  |
| D1             | 1         | 1          | Larynx      | Squamous cell carcinoma               | 2     | II    | T2N0M0  | Malignant | M   | 55  |
| D2             | 1         | 1          | Larynx      | Squamous cell carcinoma               | 2     | II    | T2N0M0  | Malignant | M   | 54  |
| Code | Age | Tumor Site | Tumor Type | Stage | Grade | Tumor Type Code | Malignant | Gender | Age Group |
|------|-----|------------|------------|-------|-------|----------------|-----------|--------|-----------|
| D4   | 1.5 | Larynx     | Squamous cell carcinoma | 2     | IV    | T4N0M0         | Malignant | M     | 65        |
| D5   | 3   | Larynx     | Squamous cell carcinoma | 2     | III   | T3N0M0         | Malignant | M     | 75        |
| D6   | 3   | Larynx     | Squamous cell carcinoma | 2     | IVA   | T4N1M0         | Malignant | M     | 64        |
| D7   | 3   | Larynx     | Squamous cell carcinoma | 3     | III   | T3N1M0         | Malignant | F     | 70        |
| D8   | 1   | Oral cavity | Squamous cell carcinoma of hypopharynx | 3 | IV | T1N1M1 | Malignant | M | 53 |
| D9   | 0   | Larynx     | Squamous cell carcinoma | 3     | III   | T2N1M0         | Malignant | M     | 54        |
| D10  | 0   | Nose       | Squamous cell carcinoma of sinus piriformis | 3 | II | T2N0M0 | Malignant | M | 50 |
| E1   | 1   | Oral cavity | Squamous cell carcinoma of maxillary sinus | 3 | IIIB | T2N1M0 | Malignant | F | 72 |
| E2   | 1.5 | Oral cavity | Squamous cell carcinoma of left maxillary sinus | 3 | I | T1N0M0 | Malignant | F | 51 |
| E3   | 3   | Larynx     | Squamous cell carcinoma | 2     | IIA   | T2N0M0         | Malignant | M     | 71        |
| E4   | 1.5 | Larynx     | Squamous cell carcinoma | 3     | IIA   | T2N0M0         | Malignant | F     | 62        |
| E5   | 3   | Larynx     | Squamous cell carcinoma | 3     | III   | T3N0M0         | Malignant | M     | 58        |
| E6   | 2.5 | Larynx     | Squamous cell carcinoma of left mandible | 3 | III | T2N0M0 | Malignant | M | 62 |
| E7   | 2   | Larynx     | Squamous cell carcinoma | 3     | IIIA  | T2N0M0         | Malignant | M     | 72        |
| E8   | 2   | Larynx     | Squamous cell carcinoma | 2     | II    | T2N0M0         | Malignant | M     | 73        |
| E9   | 3   | Larynx     | Squamous cell carcinoma | 3     | IVA   | T4N0M0         | Malignant | M     | 64        |
| F1   | 3   | Larynx     | Squamous cell carcinoma | 2     | –     | T3N2M0         | Malignant | M     | 57        |
| F2   | 1.5 | Larynx     | Squamous cell carcinoma of left nasal cavity | 2 | III | T3N0M0 | Malignant | M | 43 |
| F3   | 3   | Larynx     | Squamous cell carcinoma | 3     | III   | T3N0M0         | Malignant | M     | 71        |
| F4   | 1.5 | Larynx     | Squamous cell carcinoma | 3     | IV    | T4N1M0         | Malignant | M     | 67        |
| F5   | 3   | Larynx     | Squamous cell carcinoma | 3     | IV    | T3N2M0         | Malignant | M     | 65        |
| F6   | 1.5 | Larynx     | Squamous cell carcinoma | 3     | IV    | T4N0M0         | Malignant | M     | 68        |
| F7   | 2   | Larynx     | Squamous cell carcinoma | 2     | II    | T2N0M0         | Malignant | M     | 60        |
| F8   | 2.5 | Larynx     | Squamous cell carcinoma | 3     | IVA   | T4N1M0         | Malignant | M     | 53        |
| F9   | 3   | Oral cavity | Squamous cell carcinoma of mandible | 3 | – | – | Malignant | M | 54 |
| F10  | 2.5 | Larynx     | Squamous cell carcinoma | 3     | IV    | T4N2M0         | Malignant | M     | 53        |
| G1   | 0   | Larynx     | Squamous cell carcinoma of laryngopharynx | 3 | IV | T4N1M0 | Malignant | M | 47 |
| H1   | 0.5 | Epiglottis | Epiglottis tissue | – | – | – | Normal | M | 28 |
| H2   | 0.5 | Epiglottis | Epiglottis tissue | – | – | – | Normal | M | 41 |
| H3   | 3   | Salivary gland | Salivary gland tissue | – | – | – | Normal | M | 22 |
| H5   | 0   | Salivary gland | Salivary gland tissue | – | – | – | Normal | M | 22 |
| H6   | 0   | Salivary gland | Salivary gland tissue | – | – | – | Normal | M | 43 |
| H7   | 0   | Salivary gland | Salivary gland tissue | – | – | – | Normal | F | 15 |
| H8   | 0.5 | Larynx     | Larynx tissue | – | – | – | Normal | M | 45 |
| H9   | 0.5 | Tongue     | Tongue tissue | – | – | – | Normal | M | 16 |
| H10  | 0.5 | Tongue     | Tongue tissue | – | – | – | Normal | M | 48 |

https://www.biomax.us/tissue-arrays/Head_and_Neck/HN802a